Werewolf and Ambros Merge in $150M Deal to Advance First Potential FDA-Approved Treatment for CRPS-1

Werewolf and Ambros merge in all-stock deal with oversubscribed $150M funding to advance neridronate as potential first FDA-approved CRPS-1 treatment.